To develop non-invasive diagnostics tests to allow clinicians to safely and effectively discover cancer earlier, manage those patients that have cancer more effectively, and to allow for a greater vigilance to those patients that are in remission from this deadly disease.

By leveraging our expertise in diagnostic development, genetics, molecular biology and genomic analysis of circulating tumor cells, our company is committed to not only developing rapid and non-invasive tests for cancer but also supporting academic and corporate collaborators in their quest to uncover novel cancer gene drivers and develop next generation targeted therapies.